ARHGDIA-Related Steroid-Resistant Nephrotic Syndrome (Nephrotic Syndrome, Type 8 / NPHS8) — Research Report

Identifiers: OMIM #615244 (NPHS8); Gene: ARHGDIA, OMIM *601925, HGNC:678, UniProt P52565, chr17q25.3, GRCh38 ENSG00000141522; MONDO:0014099; Orphanet ORPHA:656 (Hereditary steroid-resistant nephrotic syndrome, parent grouping — no disease-specific ORPHA code was found for the ARHGDIA subtype specifically; it is cataloged under this broader hereditary SRNS entry and via GeneCC gene-disease submissions at thegencc.org/genes/HGNC:678); Inheritance: autosomal recessive.

1. Disease Overview

ARHGDIA-related nephrotic syndrome (NPHS8) is a genetically defined, autosomal recessive form of steroid-resistant nephrotic syndrome (SRNS) caused by biallelic loss-of-function variants in ARHGDIA, which encodes Rho GDP-dissociation inhibitor alpha (RhoGDIα/GDIα). It was established as a monogenic SRNS cause simultaneously by two independent groups in 2013: Gee et al. (PMID:23867502, J Clin Invest 123(8):3243-3253) via homozygosity mapping/whole-exome sequencing in a consanguineous family, and Gupta et al. (PMID:23434736, J Med Genet 50(5):330-338) via whole-exome sequencing of two affected sisters. Both groups independently converged on the same gene and the same podocyte cytoskeletal mechanism, which is unusually strong corroboration for a single-gene SRNS discovery.

Direct quote (Gee et al., abstract): "We combined homozygosity mapping with whole-exome resequencing and identified an ARHGDIA mutation that causes SRNS... These findings identify a single-gene cause of NS and reveal that RHO GTPase signaling is a pathogenic mediator of SRNS."

Direct quote (Gupta et al., conclusions): "Mutations in ARHGDIA need to be considered in the aetiology of heritable forms of nephrotic syndrome."

2. Etiology / Genetic Basis

Gene function. ARHGDIA's product sequesters RHOA, RAC1, and CDC42 in their inactive, GDP-bound, cytosolic form and protects them from proteasomal degradation. Gee et al.: "ARHGDIA is in a complex with RHO GTPases and is prominently expressed in podocytes of rat glomeruli."

Reported pathogenic variants (all biallelic, AR): | Variant | Type | Source | |---|---|---| | c.553_555del, p.Asp185del (ΔD185) | In-frame deletion, homozygous, two affected sisters | Gupta et al. 2013, PMID:23434736 | | p.Arg120Ter (R120X) | Nonsense | Gee et al. 2013, PMID:23867502 | | p.Gly173Val (G173V) | Missense | Gee et al. 2013, PMID:23867502 | | Additional novel variant, single case | Iranian consanguineous SRNS cohort (n=30 families) | Estiar-Nejad/colleagues cohort, PMC9555279 — reports ARHGDIA among single-case genetic causes alongside NUP205, COQ6, SGPL1, NPHP1; states one ARHGDIA variant "had not previously been reported as disease-causing" (paraphrase from search synthesis — exact primary-text confirmation of this ARHGDIA-specific detail was not independently verified by direct fetch; treat as a lead pending confirmation of full text) | | Homozygous ARHGDIA mutation, 11-month-old infant | Case report | PMID:35060086, Indian J Pediatr — abstract text could not be retrieved directly; title and indexing confirm a third clinical report of infantile-onset SRNS with a homozygous ARHGDIA variant |

Zygosity/origin: all reported cases are homozygous or compound-heterozygous germline variants, consistent with autosomal recessive, loss-of-function disease mechanism. No modifier genes, digenic interactions, or protective alleles have been reported in the literature retrieved.

Frequency among SRNS cohorts: ARHGDIA is a rare cause. In the largest reported consanguineous SRNS cohort search returned (30 Iranian families, PMC9555279), the dominant genes were NPHS1 (~30%), NPHS2 (~20%), and WT1 (~7%), with ARHGDIA appearing only in a single case — consistent with it being a minor contributor genome-wide, as expected for a gene identified from single/small pedigrees rather than large cohort screens.

3. Phenotypes

Onset: neonatal to early infancy in the founding reports — Gupta et al.'s sisters had congenital nephrotic syndrome; the case report literature includes an 11-month-old infant (PMID:35060086). OMIM's synopsis (per search-engine synthesis of the omim.org entry, direct fetch blocked by a bot-verification wall) describes "neonatal or early childhood onset steroid resistant renal disease."

Core renal phenotype: - Severe proteinuria, nephrotic-range - Hypoalbuminemia - Generalized edema - Hyperlipidemia - Progressive renal failure to end-stage kidney disease (steroid-resistant by definition — unresponsive to corticosteroid therapy)

Suggested HPO terms: HP:0000100 (Nephrotic syndrome), HP:0003155 (Elevated urine protein/proteinuria — or HP:0000093 Proteinuria), HP:0003073 (Hypoalbuminemia), HP:0003077 (Hyperlipidemia), HP:0000969 (Edema), HP:0000083 (Renal insufficiency)/HP:0000822 progression to HP:0003774 (Stage 5 chronic kidney disease), HP:0012622 (Chronic kidney disease). Onset: HP:0003623 (Neonatal onset) or HP:0410280 (Infantile onset) depending on the individual case.

Histopathology (kidney biopsy): diffuse mesangial sclerosis — small glomeruli, hypercellularity, increased extracellular matrix, contracted/collapsed glomerular tufts surrounded by immature/abnormal podocytes. Electron microscopy: diffuse foot process effacement and thinning of the glomerular basement membrane (per search synthesis of case-report content; this histologic description should be re-verified against primary-text access to the case report(s) before use as a direct quote in curation — flagged as a lead, not independently confirmed by direct source fetch).

Extrarenal involvement: None consistently reported in the human literature retrieved. Note that the mouse knockout (Togawa et al. 1999, below) additionally shows reproductive organ impairment and lymphocyte trafficking defects (Ishizaki et al. 2006, J Immunol, GDIα/GDIβ double knockout) — these are model-organism findings and have not been reported as part of the human phenotype in the literature surveyed; this is a candidate HUMAN_MODEL_MISMATCH/undetermined-translatability point rather than an established pediatric extrarenal manifestation.

4. Molecular Mechanism / Pathophysiology

Causal chain (as established by the founding papers and mechanistic follow-up):

1. Biallelic loss-of-function ARHGDIA variant (R120X, G173V, ΔD185, or other) →
2. Mutant RhoGDIα protein fails to bind RHO-family GTPases (RHOA, RAC1, CDC42) — demonstrated directly by co-immunoprecipitation/binding assays in HEK293T cells (Gupta et al.) and by loss of GTPase interaction for R120X/G173V (Gee et al.) →
3. Loss of GDIα-mediated cytosolic sequestration and protection from proteasomal degradation of RHO-GTPases →
4. Hyperactivation of GTP-bound RAC1 (most consistently and prominently implicated) and CDC42, but not RHOA — Gee et al.: "ARHGDIA mutations (R120X and G173V) ... increased active GTP-bound RAC1 and CDC42, but not RHOA, indicating that RAC1 and CDC42 are more relevant to the pathogenesis of this SRNS variant than RHOA." The follow-up mechanistic paper (Gupta, Small GTPases 2016, PMC4905261) sharpens this further: "Rac1 activity was markedly increased in GDIα KD podocytes" and Rac1 showed the most pronounced, consistent hyperactivation of the three GTPases tested across all three disease mutations. Gupta et al. 2013 additionally showed hyperactivation of all three GTPases (RhoA, Rac1, Cdc42) in patient fibroblasts and GDIα-knockdown podocytes, with GDIα mislocalized to the nucleus in the ΔD185 proband's fibroblasts.
5. Rho-GTPase (chiefly RAC1) dysregulation causes derangement of the podocyte actin cytoskeleton →
6. Altered podocyte motility — mutant GDIα enhanced migration of cultured human podocytes, an effect reversible with RAC1 inhibitors (Gee et al.) — and impaired podocyte morphology/adhesion →
7. Foot process effacement / podocyte injury and glomerular filtration barrier breakdown →
8. Proteinuria, hypoalbuminemia, edema, hyperlipidemia (nephrotic syndrome) →
9. Progressive glomerulosclerosis (diffuse mesangial sclerosis pattern) → chronic/end-stage renal failure.

Model-organism confirmation of the chain: Gee et al. recapitulated the nephrotic phenotype in arhgdia-deficient zebrafish, and RAC1 inhibitors were "partially effective in ameliorating arhgdia-associated defects" — direct evidence that step 4→6 is causally load-bearing and pharmacologically targetable, at least in the fish model. The original constitutive mouse knockout (Togawa et al. 1999, Oncogene 18:5373-5380, PMID:10498891) independently established, well before the human disease-gene discovery, that Arhgdia−/− mice "developed massive proteinuria mimicking nephrotic syndrome, leading to death due to renal failure within a year," with additional degeneration of tubular epithelial cells and progressive reproductive-organ impairment — the mouse model that first flagged this gene as renally relevant, later mined by Gupta et al. as translational justification for pursuing ARHGDIA as a human candidate gene ("Mice with targeted inactivation of ARHGDIA are known to develop severe proteinuria and nephrotic syndrome, therefore this gene was pursued in functional studies").

Molecular pathway/GO/CL suggestions: - GO:0005094 (Rho GDP-dissociation inhibitor activity) — ARHGDIA's own molecular function - GO:0007266 (Rho protein signal transduction); GO:0030036 (actin cytoskeleton organization); GO:0030334 (regulation of cell migration) - CL:0000653 (podocyte) — the principal disease-relevant cell type - Relevant downstream GTPases as distinct entities: RAC1 (HGNC:9801), CDC42 (HGNC:1736); note RHOA (HGNC:667) is implicated in in-vitro/fibroblast assays but was explicitly not hyperactivated in the podocyte/patient-derived Rho-GTPase activity assays in Gee et al., a distinction worth preserving rather than lumping all three GTPases together in a pathophysiology node.

5. Anatomical/Cellular Localization

• Organ: kidney (glomerulus) — primary and essentially sole clinically established site of disease.
• Tissue: glomerular filtration barrier / mesangium.
• Cell type: podocyte (CL:0000653), the cell type in which ARHGDIA is "prominently expressed" per both founding papers, in rat and mouse glomeruli.
• Subcellular: cytoplasm (GDIα's normal sequestering compartment for inactive GTPases) vs. pathological nuclear mislocalization of mutant GDIα reported in ΔD185 patient fibroblasts (Gupta et al.) — a notable subcellular mislocalization finding suggesting disruption of normal cytoplasmic tethering as part of the loss-of-function mechanism.

6. Diagnostics

• Clinical presentation: infantile/early-childhood nephrotic syndrome that fails to respond to corticosteroid therapy (defining "steroid-resistant" status), prompting genetic workup.
• Genetic testing: targeted single-gene sequencing or inclusion in SRNS/congenital nephrotic syndrome gene panels (alongside NPHS1, NPHS2, WT1, PLCE1, LAMB2, and others); whole-exome sequencing was the discovery method in both founding cohorts and remains the practical diagnostic route for a gene this rare (not typically first-tier on narrow panels given its low prevalence in cohorts).
• Renal biopsy: diffuse mesangial sclerosis pattern; EM shows foot process effacement — supportive but non-specific; overlaps histologically with WT1- and PLCE1-related DMS, so histology alone cannot discriminate genotype.
• No specific biomarker or functional assay for ARHGDIA deficiency is reported in a clinically validated form; functional confirmation (GTPase activity assays, fibroblast Rho-GTPase pulldown) has so far been used only in the research setting (Gupta et al.'s proband fibroblast studies), not as a routine diagnostic.

7. Treatment / Prognosis

• No disease-specific approved therapy exists. Standard nephrotic-syndrome supportive management applies (ACE inhibitor/ARB for proteinuria reduction, management of edema/hyperlipidemia, and ultimately renal replacement therapy/transplantation for progression to ESKD), consistent with general SRNS management principles; the literature retrieved contains no ARHGDIA-specific clinical trial or approved pharmacotherapy.
• Experimental/mechanistic therapeutic signal: RAC1 inhibition. Gee et al. showed pharmacological RAC1 inhibition reversed the enhanced podocyte migration phenotype in vitro and was "partially effective in ameliorating arhgdia-associated defects" in the zebrafish model — this is model-system evidence for a targeted mechanism-based therapeutic strategy, not a clinically validated treatment; would map to a HUMAN_MODEL_MISMATCH/emerging hypothesis framing rather than an established treatment entry.
• Renal transplantation: general literature confirms recurrent nephrotic syndrome/FSGS after transplant is a recognized risk in genetic SRNS broadly (~30–40% depending on native histology), but no ARHGDIA-specific post-transplant recurrence case was identified in the searches performed; this should be recorded as a gap rather than inferred from the general SRNS transplant-recurrence literature.

8. Animal/Model Organism Summary

The mouse constitutive knockout is notably the oldest piece of evidence in this entire causal chain (1999) — it identified the renal phenotype 14 years before the gene was linked to human disease, making it an unusually direct instance of animal-model-first gene discovery being retrospectively validated in humans. Model fidelity is high for the core proteinuria/glomerular phenotype but the mouse model's additional reproductive and immune phenotypes have no reported human correlate and should not be imported into the human pathograph without qualification.

9. Notable Gaps / Items Requiring Further Verification Before KB Entry

• Full-text confirmation of the Iranian cohort paper's (PMC9555279) specific ARHGDIA variant, zygosity, and patient-level clinical detail — direct fetch was blocked (reCAPTCHA); only search-engine synthesis was obtained, which per this repository's evidence standards is not an exact quotable snippet and must be re-fetched (e.g., via just fetch-reference) before citation.
• PMID:35060086 (Indian J Pediatr case report) abstract text could not be retrieved directly (fetch attempts returned only citation metadata or server errors); title/indexing confirm its existence and relevance but no quotable snippet was obtained.
• OMIM #615244's full clinical synopsis could not be directly fetched (bot-verification wall on omim.org); the clinical description used above is a search-engine paraphrase of the OMIM entry and should be re-verified against the primary OMIM text (or GeneReviews, if one exists — none was identified in these searches) before use as a cited snippet.
• No dedicated Orphanet disease-specific code (distinct from the broader ORPHA:656 "Hereditary steroid-resistant nephrotic syndrome" grouping) was confirmed for the ARHGDIA subtype specifically.
• Prevalence/incidence figures specific to NPHS8 were not found in any source; it appears only as single-case/single-family reports (three independent pedigrees/cases identified: the original consanguineous family, two sisters, the Iranian single case, and the Indian infant case report), consistent with an ultra-rare designation, but no formal prevalence class (Orphanet-style) was located.

Sources

• Entry - #615244 - NEPHROTIC SYNDROME, TYPE 8; NPHS8 - OMIM
• Entry - *601925 - RHO GDP-DISSOCIATION INHIBITOR ALPHA; ARHGDIA - OMIM
• ARHGDIA: a novel gene implicated in nephrotic syndrome - PubMed (PMID:23434736)
• ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling - PubMed (PMID:23867502)
• JCI - ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling (full text)
• Disease-causing mutations of RhoGDIα induce Rac1 hyperactivation in podocytes - PMC (PMC4905261)
• Europe PMC record for PMID:23867502 (abstract)
• Europe PMC record for PMID:23434736 (abstract)
• Homozygous ARHGDIA Gene Mutation in an 11-Month-Old Infant with Steroid-Resistant Nephrotic Syndrome - PubMed (PMID:35060086)
• High detection rate for disease-causing variants in a cohort of 30 Iranian pediatric steroid resistant nephrotic syndrome cases - PMC
• Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha - PubMed (PMID:10498891)
• ARHGDIA gene with submissions organized by classifications - GenCC
• ARHGDIA gene - GeneCards
• Orphanet: ARHGDIA - Rho GDP dissociation inhibitor alpha
• Gene: ARHGDIA (ENSG00000141522) - Ensembl
• pharos.nih.gov MIM:615244
• Gene–disease relationships for glomerular phenotypes: expert recommendations from ClinGen - Nature Reviews Nephrology

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0410280 (1 mention) - the report calls it "Infantile onset"; HP calls it Pediatric onset
• CL:0000653 (2 mentions) - the report calls it "podocyte", "Cell type: podocyte"; CL calls it podocyte, and lists "renal podocyte" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• CL:0000653 - called "podocyte", "Cell type: podocyte"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, EXT_ID, MIM.

18 of 26 terms resolved to a current term; the rest could not be looked up either way.